Hosted on MSN2mon
Palvella Therapeutics Reports Promising Results for QTORIN Rapamycin in Treating Rare Genetic Diseasehas the potential to become the first approved therapy for this rare and debilitating disease in the United States. Microcystic LMs are a genetic condition caused by disruptions in the PI3K/mTOR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback